Bayesian predictive model averaging approach to joint longitudinal-survival modeling: application to an immuno-oncology clinical trial
From MaRDI portal
Publication:6560489
DOI10.1002/sim.9897zbMath1540.62199MaRDI QIDQ6560489
Sumiyuki Nishida, Zixuan Yao, Satoshi Morita, Haruo Sugiyama
Publication date: 23 June 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
random effectsBayesian model averagingtime-to-event datajoint modelingmultiple longitudinal outcomes
Cites Work
- Unnamed Item
- Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC
- Bayesian model averaging: A tutorial. (with comments and a rejoinder).
- Using stacking to average Bayesian predictive distributions (with discussion)
- Joint models with multiple longitudinal outcomes and a time-to-event outcome: a corrected two-stage approach
- Quantile regression-based Bayesian joint modeling analysis of longitudinal-survival data, with application to an AIDS cohort study
- Fully Exponential Laplace Approximations for the Joint Modelling of Survival and Longitudinal Data
- A Bayesian Semiparametric Joint Hierarchical Model for Longitudinal and Survival Data
- Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time-to-Event Data
- Quantifying and comparing dynamic predictive accuracy of joint models for longitudinal marker and time‐to‐event in presence of censoring and competing risks
- Bayesian Inference in Semiparametric Mixed Models for Longitudinal Data
- A Predictive Approach to Model Selection
- Bayesian joint modeling of bivariate longitudinal and competing risks data: An application to study patient‐ventilator asynchronies in critical care patients
- Comparison of joint modeling and landmarking for dynamic prediction under an illness‐death model
- Graphical calibration curves and the integrated calibration index (ICI) for survival models
This page was built for publication: Bayesian predictive model averaging approach to joint longitudinal-survival modeling: application to an immuno-oncology clinical trial